search
Back to results

Telmisartan in Mild to Moderate Hypertensive Patients

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Low dose of telmisartan
High dose of telmisartan
Placebo
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with blood pressure levels of 140/90 mm Hg or higher (confirmed on 2 consecutive visits), who were 18 years old and older, regardless of sex

Exclusion Criteria:

  • Suspected or known diagnosis of arterial hypertension with a secondary cause
  • Women who were not using an effective method of contraception, or who were pregnant, or breast-feeding
  • Systolic blood pressure > 200 mm Hg or diastolic blood pressure > 115 mm Hg
  • Laboratory test values two fold above the upper normal limit
  • Previous intolerance to angiotensin conversion enzyme inhibitors or angiotensin II blocker (AIIAR)
  • New York Heart Association class III or IV heart failure
  • History of stroke in the 6 months prior to entry into the study
  • Uncontrolled type 2 diabetes mellitus, defined as fasting glucose levels > 140 mg/dL on 3 consecutive assessments
  • Patients who were included in another investigational drug study in the past 30 days

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Experimental

    Arm Label

    Low dose of telmisartan

    High dose of telmisartan

    Arm Description

    4 week placebo run-in phase followed by 6 weeks of treatment with low dose of telmisartan

    After 6 weeks of treatment with low dose of telmisartan, titration to high dose of telmisartan if blood pressure level is higher than 140/90 mm Hg

    Outcomes

    Primary Outcome Measures

    Changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP)
    Blood pressure values were obtained 24 hours after the last dose (through values) at the office

    Secondary Outcome Measures

    Assessment of treatment response for SBP/DBP (in %)
    Response categories: SBP < 140 mm Hg or DBP < 90 mm Hg or BP reduction ≥ 10 mm Hg
    Changes from baseline in blood pressure values
    Analysis performed for the ambulatory blood pressure monitoring (ABPM) - subgroup
    Number of patients with adverse events
    Number of patients with clinically significant changes in laboratory values
    Number of patients with clinically significant changes in ECG

    Full Information

    First Posted
    October 8, 2014
    Last Updated
    October 8, 2014
    Sponsor
    Boehringer Ingelheim
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02260089
    Brief Title
    Telmisartan in Mild to Moderate Hypertensive Patients
    Official Title
    A Multicenter Open-label Study of the Efficacy and Safety of Telmisartan in Mild to Moderate Hypertensive Patients
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    October 2014
    Overall Recruitment Status
    Completed
    Study Start Date
    March 2000 (undefined)
    Primary Completion Date
    July 2002 (Actual)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Boehringer Ingelheim

    4. Oversight

    5. Study Description

    Brief Summary
    To evaluate the efficacy and tolerability of telmisartan, given once a day to patients with mild to moderate hypertension, as well as to assess the 24-hour blood pressure profile with ABPM

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hypertension

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    134 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Low dose of telmisartan
    Arm Type
    Experimental
    Arm Description
    4 week placebo run-in phase followed by 6 weeks of treatment with low dose of telmisartan
    Arm Title
    High dose of telmisartan
    Arm Type
    Experimental
    Arm Description
    After 6 weeks of treatment with low dose of telmisartan, titration to high dose of telmisartan if blood pressure level is higher than 140/90 mm Hg
    Intervention Type
    Drug
    Intervention Name(s)
    Low dose of telmisartan
    Intervention Type
    Drug
    Intervention Name(s)
    High dose of telmisartan
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo
    Primary Outcome Measure Information:
    Title
    Changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP)
    Description
    Blood pressure values were obtained 24 hours after the last dose (through values) at the office
    Time Frame
    Baseline, up to 12 weeks after start of treatment
    Secondary Outcome Measure Information:
    Title
    Assessment of treatment response for SBP/DBP (in %)
    Description
    Response categories: SBP < 140 mm Hg or DBP < 90 mm Hg or BP reduction ≥ 10 mm Hg
    Time Frame
    Baseline, up to 12 weeks after start of treatment
    Title
    Changes from baseline in blood pressure values
    Description
    Analysis performed for the ambulatory blood pressure monitoring (ABPM) - subgroup
    Time Frame
    Baseline, up to 12 weeks after start of treatment
    Title
    Number of patients with adverse events
    Time Frame
    Up to 16 weeks
    Title
    Number of patients with clinically significant changes in laboratory values
    Time Frame
    Up to 16 weeks
    Title
    Number of patients with clinically significant changes in ECG
    Time Frame
    Up to 16 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Patients with blood pressure levels of 140/90 mm Hg or higher (confirmed on 2 consecutive visits), who were 18 years old and older, regardless of sex Exclusion Criteria: Suspected or known diagnosis of arterial hypertension with a secondary cause Women who were not using an effective method of contraception, or who were pregnant, or breast-feeding Systolic blood pressure > 200 mm Hg or diastolic blood pressure > 115 mm Hg Laboratory test values two fold above the upper normal limit Previous intolerance to angiotensin conversion enzyme inhibitors or angiotensin II blocker (AIIAR) New York Heart Association class III or IV heart failure History of stroke in the 6 months prior to entry into the study Uncontrolled type 2 diabetes mellitus, defined as fasting glucose levels > 140 mg/dL on 3 consecutive assessments Patients who were included in another investigational drug study in the past 30 days

    12. IPD Sharing Statement

    Links:
    URL
    http://trials.boehringer-ingelheim.com
    Description
    Related Info

    Learn more about this trial

    Telmisartan in Mild to Moderate Hypertensive Patients

    We'll reach out to this number within 24 hrs